Johnson, Scott; Kaltenboeck, Anna; Diener, Melissa; … - In: PharmacoEconomics 31 (2013) 9, pp. 799-806
Direct costs for newly diagnosed PD patients exceeded costs for controls without PD, and increased with PD progression. Direct costs were approximately 6–7 times higher in patients with advanced PD than in matched controls. Indirect costs represented 45 % of total excess costs for newly...